Biocardia Price To Sales Ratio vs Capex To Revenue Analysis

BCDA Stock  USD 2.16  0.11  4.85%   
Biocardia financial indicator trend analysis is way more than just evaluating Biocardia prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biocardia is a good investment. Please check the relationship between Biocardia Price To Sales Ratio and its Capex To Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.

Price To Sales Ratio vs Capex To Revenue

Price To Sales Ratio vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biocardia Price To Sales Ratio account and Capex To Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Biocardia's Price To Sales Ratio and Capex To Revenue is -0.07. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Biocardia, assuming nothing else is changed. The correlation between historical values of Biocardia's Price To Sales Ratio and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Biocardia are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Price To Sales Ratio i.e., Biocardia's Price To Sales Ratio and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

-0.07
Relationship DirectionNegative 
Relationship StrengthInsignificant

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Biocardia stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Biocardia sales, a figure that is much harder to manipulate than other Biocardia multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.
Most indicators from Biocardia's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biocardia current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.At present, Biocardia's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 12.57, whereas Selling General Administrative is forecasted to decline to about 3.3 M.
 2021 2022 2023 2024 (projected)
Interest Expense9K6K6.9K6.6K
Depreciation And Amortization640K82K84K79.8K

Biocardia fundamental ratios Correlations

0.02-0.140.96-0.15-0.970.16-0.240.99-0.26-0.610.990.30.54-0.120.230.12-0.06-0.2-0.370.990.540.650.070.51-0.19
0.020.82-0.240.90.19-0.750.45-0.110.840.4-0.110.05-0.64-0.120.840.530.730.850.69-0.08-0.640.070.860.02-0.7
-0.140.82-0.420.750.34-0.940.8-0.270.780.48-0.27-0.08-0.710.070.780.510.930.980.7-0.23-0.71-0.20.87-0.38-0.89
0.96-0.24-0.42-0.39-0.990.42-0.440.99-0.49-0.710.990.320.7-0.14-0.02-0.05-0.33-0.47-0.570.980.690.64-0.190.560.07
-0.150.90.75-0.390.36-0.790.4-0.270.960.57-0.27-0.19-0.58-0.120.70.430.760.850.89-0.26-0.57-0.020.74-0.18-0.59
-0.970.190.34-0.990.36-0.350.35-1.00.460.72-1.0-0.32-0.660.09-0.030.020.250.40.55-0.99-0.65-0.650.12-0.550.01
0.16-0.75-0.940.42-0.79-0.35-0.780.27-0.83-0.580.270.220.60.0-0.68-0.41-0.99-0.95-0.80.250.590.2-0.810.510.89
-0.240.450.8-0.440.40.35-0.78-0.320.450.29-0.32-0.31-0.560.350.390.30.760.750.43-0.29-0.56-0.190.63-0.39-0.71
0.99-0.11-0.270.99-0.27-1.00.27-0.32-0.38-0.671.00.310.62-0.110.110.02-0.18-0.33-0.471.00.620.65-0.050.53-0.08
-0.260.840.78-0.490.960.46-0.830.45-0.380.73-0.38-0.24-0.61-0.170.670.430.810.880.97-0.37-0.61-0.250.73-0.41-0.6
-0.610.40.48-0.710.570.72-0.580.29-0.670.73-0.67-0.27-0.53-0.470.250.10.540.550.8-0.67-0.52-0.780.36-0.74-0.27
0.99-0.11-0.270.99-0.27-1.00.27-0.321.0-0.38-0.670.310.62-0.110.110.02-0.18-0.33-0.471.00.620.65-0.050.53-0.08
0.30.05-0.080.32-0.19-0.320.22-0.310.31-0.24-0.270.31-0.11-0.280.38-0.37-0.2-0.18-0.410.32-0.120.120.120.33-0.12
0.54-0.64-0.710.7-0.58-0.660.6-0.560.62-0.61-0.530.62-0.11-0.13-0.56-0.22-0.53-0.7-0.540.61.00.35-0.730.280.46
-0.12-0.120.07-0.14-0.120.090.00.35-0.11-0.17-0.47-0.11-0.28-0.13-0.20.18-0.030.07-0.15-0.1-0.130.360.00.180.03
0.230.840.78-0.020.7-0.03-0.680.390.110.670.250.110.38-0.56-0.20.370.690.760.480.14-0.560.050.82-0.06-0.82
0.120.530.51-0.050.430.02-0.410.30.020.430.10.02-0.37-0.220.180.370.420.530.410.06-0.220.10.48-0.04-0.36
-0.060.730.93-0.330.760.25-0.990.76-0.180.810.54-0.18-0.2-0.53-0.030.690.420.930.77-0.16-0.53-0.180.81-0.51-0.91
-0.20.850.98-0.470.850.4-0.950.75-0.330.880.55-0.33-0.18-0.70.070.760.530.930.81-0.3-0.7-0.210.85-0.4-0.83
-0.370.690.7-0.570.890.55-0.80.43-0.470.970.8-0.47-0.41-0.54-0.150.480.410.770.81-0.47-0.53-0.350.61-0.55-0.49
0.99-0.08-0.230.98-0.26-0.990.25-0.291.0-0.37-0.671.00.320.6-0.10.140.06-0.16-0.3-0.470.590.65-0.020.53-0.11
0.54-0.64-0.710.69-0.57-0.650.59-0.560.62-0.61-0.520.62-0.121.0-0.13-0.56-0.22-0.53-0.7-0.530.590.34-0.730.270.46
0.650.07-0.20.64-0.02-0.650.2-0.190.65-0.25-0.780.650.120.350.360.050.1-0.18-0.21-0.350.650.340.00.80.02
0.070.860.87-0.190.740.12-0.810.63-0.050.730.36-0.050.12-0.730.00.820.480.810.850.61-0.02-0.730.0-0.13-0.81
0.510.02-0.380.56-0.18-0.550.51-0.390.53-0.41-0.740.530.330.280.18-0.06-0.04-0.51-0.4-0.550.530.270.8-0.130.32
-0.19-0.7-0.890.07-0.590.010.89-0.71-0.08-0.6-0.27-0.08-0.120.460.03-0.82-0.36-0.91-0.83-0.49-0.110.460.02-0.810.32
Click cells to compare fundamentals

Biocardia Account Relationship Matchups

Biocardia fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets7.7M23.4M15.7M9.8M3.0M2.8M
Other Current Liab1.8M2.2M2.9M3.0M1.3M806.1K
Total Current Liabilities4.0M4.2M3.7M3.6M3.6M3.8M
Total Stockholder Equity2.4M19.2M10.4M4.9M(1.6M)(1.5M)
Property Plant And Equipment Net1.2M712K2.1M1.9M1.4M744.1K
Net Debt(4.4M)(20.8M)(11.0M)(5.7M)212K222.6K
Retained Earnings(101.1M)(116.1M)(128.7M)(140.6M)(152.2M)(144.6M)
Accounts Payable914K746K507K683K890K934.5K
Cash5.6M21.4M12.9M7.4M1.1M1.0M
Non Current Assets Total1.3M766K2.2M1.9M1.5M1.6M
Cash And Short Term Investments5.6M21.4M12.9M7.4M1.1M1.0M
Net Receivables274K147K850K201K63K59.9K
Common Stock Total Equity38K43K7K16K18.4K17.5K
Common Stock Shares Outstanding5.6M674.6K1.1M1.2M1.4M1.4M
Liabilities And Stockholders Equity7.7M23.4M15.7M9.8M3.0M2.8M
Non Current Liabilities Total1.3M2.7M1.6M1.3M982K630.9K
Other Current Assets642K401K924K300K295K436.7K
Other Stockholder Equity103.4M135.2M139.1M145.5M150.5M158.1M
Total Liab5.3M4.2M5.3M4.9M4.6M4.8M
Total Current Assets6.4M22.7M13.5M7.9M1.5M1.4M
Common Stock7K16K17K20K24K22.8K
Current Deferred Revenue732K1.4M1.5M965K759K750.8K
Inventory4K(850K)1.0(201K)(180.9K)(171.9K)
Net Tangible Assets2.4M19.2M10.4M4.9M5.6M5.5M
Retained Earnings Total Equity(72.5M)(86.4M)(101.1M)(116.1M)(104.5M)(99.2M)
Capital Surpluse83.5M90.1M103.4M135.2M155.5M163.3M
Property Plant Equipment1.2M712K2.1M1.8M2.0M2.1M
Net Invested Capital2.4M19.2M10.4M4.9M(1.6M)(1.5M)
Net Working Capital2.4M18.4M9.8M4.3M(2.1M)(2.0M)
Capital Stock7K16K17K20K24K16.9K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.03)
Revenue Per Share
0.264
Quarterly Revenue Growth
(0.93)
Return On Assets
(1.16)
Return On Equity
(7.04)
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocardia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.